Cargando…

Hormonal Regulation of Semaphorin 7a Promotes Therapeutic Resistance in Breast Cancer

Background: The majority of all breast cancers (BC) are estrogen receptor positive (ER+). While ER-targeting endocrine therapies have improved patient survival, many of these tumors develop drug resistance and recur within 20 years. Therefore, novel targets are needed to predict for recurrence and t...

Descripción completa

Detalles Bibliográficos
Autores principales: Crump, Lyndsey, Richer, Jennifer K, Porter, Weston, Lyons, Traci
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8089171/
http://dx.doi.org/10.1210/jendso/bvab048.2090
_version_ 1783686983926677504
author Crump, Lyndsey
Richer, Jennifer K
Porter, Weston
Lyons, Traci
author_facet Crump, Lyndsey
Richer, Jennifer K
Porter, Weston
Lyons, Traci
author_sort Crump, Lyndsey
collection PubMed
description Background: The majority of all breast cancers (BC) are estrogen receptor positive (ER+). While ER-targeting endocrine therapies have improved patient survival, many of these tumors develop drug resistance and recur within 20 years. Therefore, novel targets are needed to predict for recurrence and to treat recurrent ER+BC. Previous reports describe a tumor-promotional role for Semaphorin 7A (SEMA7A) in ER- disease; yet, the role of SEMA7A in ER+ disease is poorly characterized. Hypothesis: SEMA7A promotes cell survival and drug resistance in ER+ BC. Methods: We overexpressed SEMA7A in ER+ BC cells, then used the ER-targeting agents tamoxifen and fulvestrant to test how SEMA7A-expressing cells respond to endocrine therapy. In vitro, we used proliferation and cell survival assays. In vivo, we implanted ER+ BC cells, then treated the animals with fulvestrant to measure how SEMA7A affects tumor growth and metastasis. We also utilized drug resistant cells, which have high endogenous SEMA7A levels, to measure markers of stemness and multi-drug resistance via flow cytometry. Results: We first found that SEMA7A expression correlates with decreased relapse free survival in patients with ER+BC who received endocrine therapy (Kmplotter; p=0.042). We also observe that SEMA7A is hormonally regulated in ER+BC, but its expression does not uniformly decrease with endocrine therapy agents. Instead, long term estrogen deprivation and ER-targeting drug treatments increase SEMA7A expression, likely through the action of other hormone receptors such as the androgen receptor, which also increases with long term estrogen deprivation. Further, in ER+ cell lines, overexpression of SEMA7A promotes in vitro growth in the face of estrogen-deprivation, tamoxifen, or fulvestrant treatments. In vivo, SEMA7A promotes fulvestrant resistance in the primary tumor and induces lung metastases. Finally, we report that pro-survival signaling is a therapeutic vulnerability of ER+SEMA7A+ tumors. Conclusion: These studies describe that SEMA7A promotes drug resistance in ER+ BC. We propose that targeting pro-survival signaling may prove efficacious for treating SEMA7A+ tumors, which are less likely to respond to endocrine therapies.
format Online
Article
Text
id pubmed-8089171
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-80891712021-05-06 Hormonal Regulation of Semaphorin 7a Promotes Therapeutic Resistance in Breast Cancer Crump, Lyndsey Richer, Jennifer K Porter, Weston Lyons, Traci J Endocr Soc Tumor Biology Background: The majority of all breast cancers (BC) are estrogen receptor positive (ER+). While ER-targeting endocrine therapies have improved patient survival, many of these tumors develop drug resistance and recur within 20 years. Therefore, novel targets are needed to predict for recurrence and to treat recurrent ER+BC. Previous reports describe a tumor-promotional role for Semaphorin 7A (SEMA7A) in ER- disease; yet, the role of SEMA7A in ER+ disease is poorly characterized. Hypothesis: SEMA7A promotes cell survival and drug resistance in ER+ BC. Methods: We overexpressed SEMA7A in ER+ BC cells, then used the ER-targeting agents tamoxifen and fulvestrant to test how SEMA7A-expressing cells respond to endocrine therapy. In vitro, we used proliferation and cell survival assays. In vivo, we implanted ER+ BC cells, then treated the animals with fulvestrant to measure how SEMA7A affects tumor growth and metastasis. We also utilized drug resistant cells, which have high endogenous SEMA7A levels, to measure markers of stemness and multi-drug resistance via flow cytometry. Results: We first found that SEMA7A expression correlates with decreased relapse free survival in patients with ER+BC who received endocrine therapy (Kmplotter; p=0.042). We also observe that SEMA7A is hormonally regulated in ER+BC, but its expression does not uniformly decrease with endocrine therapy agents. Instead, long term estrogen deprivation and ER-targeting drug treatments increase SEMA7A expression, likely through the action of other hormone receptors such as the androgen receptor, which also increases with long term estrogen deprivation. Further, in ER+ cell lines, overexpression of SEMA7A promotes in vitro growth in the face of estrogen-deprivation, tamoxifen, or fulvestrant treatments. In vivo, SEMA7A promotes fulvestrant resistance in the primary tumor and induces lung metastases. Finally, we report that pro-survival signaling is a therapeutic vulnerability of ER+SEMA7A+ tumors. Conclusion: These studies describe that SEMA7A promotes drug resistance in ER+ BC. We propose that targeting pro-survival signaling may prove efficacious for treating SEMA7A+ tumors, which are less likely to respond to endocrine therapies. Oxford University Press 2021-05-03 /pmc/articles/PMC8089171/ http://dx.doi.org/10.1210/jendso/bvab048.2090 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of the Endocrine Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Tumor Biology
Crump, Lyndsey
Richer, Jennifer K
Porter, Weston
Lyons, Traci
Hormonal Regulation of Semaphorin 7a Promotes Therapeutic Resistance in Breast Cancer
title Hormonal Regulation of Semaphorin 7a Promotes Therapeutic Resistance in Breast Cancer
title_full Hormonal Regulation of Semaphorin 7a Promotes Therapeutic Resistance in Breast Cancer
title_fullStr Hormonal Regulation of Semaphorin 7a Promotes Therapeutic Resistance in Breast Cancer
title_full_unstemmed Hormonal Regulation of Semaphorin 7a Promotes Therapeutic Resistance in Breast Cancer
title_short Hormonal Regulation of Semaphorin 7a Promotes Therapeutic Resistance in Breast Cancer
title_sort hormonal regulation of semaphorin 7a promotes therapeutic resistance in breast cancer
topic Tumor Biology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8089171/
http://dx.doi.org/10.1210/jendso/bvab048.2090
work_keys_str_mv AT crumplyndsey hormonalregulationofsemaphorin7apromotestherapeuticresistanceinbreastcancer
AT richerjenniferk hormonalregulationofsemaphorin7apromotestherapeuticresistanceinbreastcancer
AT porterweston hormonalregulationofsemaphorin7apromotestherapeuticresistanceinbreastcancer
AT lyonstraci hormonalregulationofsemaphorin7apromotestherapeuticresistanceinbreastcancer